Cited by 156Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolismIron Metabolism and Disorders

The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.

Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study

Oestreicher, E., Sengstock, G.J., Riederer, P., Olanow, C.W., Dunn, A.J., Arendash, G.W.·1994·Brain Research

DOI 10.1016/0006-8993(94)90833-8

Open this paper in CoChat — free account

Abstract

Parkinson's-diseased (PD) brains have increased levels of iron in the zona compacta of the substantia nigra (SNc). To determine whether these elevated nigral iron levels may be caused secondarily by degeneration of nigrostriatal dopaminergic (NS-DA) neurons, the NS-DA pathway was unilaterally lesioned in rats through 6-hydroxydopamine (6-OHDA) infusion and nigral iron levels evaluated three weeks later. A significant increase was observed in both iron concentration (+35%) and iron content (+33) within the substantia nigra (SN) ipsilateral to comprehensive 6-OHDA lesions. Moreover, ferric iron staining was dramatically increased within the SNc following 6-OHDA lesions, primarily due to the appearance of iron-positive SNc neurons and infiltrating reactive glial cells. Iron staining in the SN zona reticularis was modestly increased after 6-OHDA lesions, but staining in the neostriatum and globus pallidus was unaffected. These results indicate that loss of NS-DA neurons is associated with increased iron levels in the SN. This suggests that increased nigral iron levels in PD may be secondary to some neurodegenerative process. Nonetheless, even a secondary increase in nigral iron levels may be of pathogenic importance in PD because of iron's ability to catalyze neurotoxic free radical formation and perpetuate neurodegeneration.

Integrity signals

Registry

Crossref · 10.1016/0006-8993(94)90833-8

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
The effect of age on the non-haemin iron in the human brain
Hallgren, B., & Sourander, P. (1958) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1958.tb12607.x · Cited by 1,427
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia
DEXTER, D. T., CARAYON, A., JAVOY-AGID, F., AGID, Y., WELLS, F. R., DANIEL, S. E., LEES, A. J., JENNER, P., & MARSDEN, C. D. (1991) · Brain · doi:10.1093/brain/114.4.1953 · Cited by 1,043
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
Sofic, E., Riederer, P. F., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G. F., & Youdim, M. B. H. (1988) · Journal of Neural Transmission · doi:10.1007/bf01244786 · Cited by 754

Show all 47 references

Research works printed but not linked: 1

Antonini, 1993, Brain iron uptake in patients with Parkinson's disease (PD) measured by positron emmission tomography (PET), J. Cereb. Blood Flow Metab., 13, S364

Sorted by citations

Items 101–156 of 156

Redox stress and metal dys-homeostasis appear as hallmarks of early prion disease pathogenesis in mice
Spiers, J. G., Chen, H. C., Barry, T. L., Bourgognon, J.-M., & Steinert, J. R. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.025 · Cited by 24
Mapping Chemical Elements and Iron Oxidation States in the Substantia Nigra of 6-Hydroxydopamine Lesioned Rats Using Correlative Immunohistochemistry With Proton and Synchrotron Micro-Analysis
Carmona, A., Roudeau, S., Perrin, L., Carcenac, C., Vantelon, D., Savasta, M., & Ortega, R. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01014 · Cited by 24
Limited Potentiation of Blood Pressure in Response to Oral Tyramine by the Anti-Parkinson Brain Selective Multifunctional Monoamine Oxidase-AB Inhibitor, M30
Gal, S., Abassi, Z. A., & Youdim, M. B. H. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9128-8 · Cited by 24
New horizons in molecular mechanisms underlying Parkinson’s disease and in our understanding of the neuroprotective effects of selegiline
Gerlach, M., Desser, H., Youdim, M. B. H., & Riederer, P. F. (1996) · Springer eBooks · doi:10.1007/978-3-7091-7494-4_2 · Cited by 22
Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinson’s disease: a Complete Review
Mehan, S., Kaur, G., Dudi, R., Rajput, M., & Kalra, S. (2017) · Open Journal of Parkinson s Disease and Treatment · doi:10.17352/ojpdt.000001 · Cited by 19
The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson’s disease
Müller, T. H., & Riederer, P. F. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02666-x · Cited by 18
Iron and cell death in Parkinson’s disease: a nuclear microscopic study into iron-rich granules in the parkinsonian substantia nigra of primate models
Thong, P. S. P., Watt, F., Ponraj, D., Leong, S. K., He, Y., & Lee, T. K. Y. (1999) · Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms · doi:10.1016/s0168-583x(99)00390-0 · Cited by 18
Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity
Fredriksson, A., Schröder, N., & Archer, T. (2003) · Neurotoxicity Research · doi:10.1007/bf03033373 · Cited by 17
2‐Benzazepine Nitrones Protect Dopaminergic Neurons against 6‐Hydroxydopamine‐Induced Oxidative Toxicity
Soto‐Otero, R., Méndez‐Álvarez, E., Sánchez‐Iglesias, S., Labandeira-García, J. L., Rodríguez‐Pallares, J., Zubkov, F. I., Zaytsev, V. P., Voskressensky, L. G., Varlamov, A. V., de Candia, M., et al. (2012) · Archiv der Pharmazie · doi:10.1002/ardp.201200007 · Cited by 16
Time-course and localization of transferrin receptor expression in the substantia nigra of 6-hydroxydopamine-induced parkinsonian rats
He, Y., Lee, T., & Leong, S. K. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00669-1 · Cited by 16
6-hydroxydopamine-induced model of Parkinson's disease
Kaczyńska, K., & Andrzejewski, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815950-7.00040-0 · Cited by 15
Clinical Characteristics, Iron Metabolism and Neuroinflammation: New Insight into Excessive Daytime Sleepiness in Parkinson’s Disease
Hu, Y., Guo, P. F., Lian, T., Zuo, L.-J., Yu, S., Liu, L., Jin, Z. Y., Yu, Q.-J., Wang, R., Li, L., et al. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s272110 · Cited by 14
Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson’s disease
Shackelford, R. E., Manuszak, R. P., Heard, S. C., Link, C. J., & Wang, S. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.08.029 · Cited by 14
Neuropathology and behavioral impairments in Wistar rats with a 6-OHDA lesion in the substantia nigra compacta and exposure to a static magnetic field
Bertolino, G., de Souza, H. C. D., & de Araújo, J. E. (2013) · Electromagnetic Biology and Medicine · doi:10.3109/15368378.2012.751394 · Cited by 14
Effects of R‐ and S‐apomorphine on MPTP‐induced nigro‐striatal dopamine neuronal loss
Grünblatt, E., Mandel, S. A., Maor, G., & Youdim, M. B. H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00227.x · Cited by 14
Targeting Mitochondrial Metal Dyshomeostasis for the Treatment of Neurodegeneration
Liddell, J. R. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.15.19 · Cited by 13
Neuroprotection in Parkinson's Disease: A Systematic Review of the Preclinical Data
Douna, H., Bavelaar, B. M., Pellikaan, H., Olivier, B., & Pieters, T. (2012) · The Open Pharmacology Journal · doi:10.2174/1874143601206010012 · Cited by 13
Oxidative Stress Indices in Parkinson's Disease: Biochemical Determination
Youdim, M. B. H., Driguès, N., & Mandel, S. A. (2003) · Humana Press eBooks · doi:10.1385/1-59259-142-6:137 · Cited by 11
The effects of iron loading and iron deficiency on the tissue uptake of 64Cu during development in the rat
Crowe, A. P., & Morgan, E. H. (1996) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(96)00044-x · Cited by 10
In silico evidence for glutathione- and iron-related pathogeneses in Parkinson's disease
Yeager, M. P., & Coleman, R. A. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.01.034 · Cited by 9
Redox Modulation of Mitochondrial Proteins in the Neurotoxicant Models of Parkinson's Disease
Sarkar, A., Rasheed, M. S. U., & Singh, M. P. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0106 · Cited by 9
The application of bathophenanthroline for the determination of free iron in parallel with hROS in microdialysis samples
Freinbichler, W., Misini, B., Colivicchi, M. A., Linert, W., Tipton, K. F., & Corte, L. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2019.108530 · Cited by 9
Role of Selenium, Iron, Copper, and Zinc in Parkinsonism
Qureshi, G. A., Syed, S. A., & Parvez, S. H. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50171-x · Cited by 8
In vitro evidence supporting the therapeutic role of nicotine against neurodegeneration.
Williams, E., & Linert, W. (2004) · PubMed · Cited by 7
Caenorhabditis Elegans Models of Parkinson's Disease
Nass, R., & Settivari, R. S. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00026-9 · Cited by 6
Chapter 25 – Green and Black Tea in Brain Protection
Ostrowska, J., Łuczaj, W., Augustyniak, A., & Skrzydlewska, E. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50166-6 · Cited by 3
Contribution of Disturbed Iron Metabolism to the Pathogenesis of Parkinson‘s Disease
Berg, D., Riederer, P. F., & Gerlach, M. (2008) · Future Neurology · doi:10.2217/14796708.3.4.447 · Cited by 4
Beneficial effects of phenolic compounds from fruit and vegetables in neurodegenerative diseases
Singh, M., & Ramassamy, C. (2008) · Elsevier eBooks · doi:10.1533/9781845694289.2.145 · Cited by 5
Brain Iron and other Trace Metals in Neurodegenerative Diseases
Gerlach, M., Youdim, M. B. H., & Riederer, P. F. (2000) · Springer eBooks · doi:10.1007/978-1-4615-1269-1_25 · Cited by 4
Biomarkers for Early Detection of Parkinson’s Disease: An Essential Challenge
Tribl, F., & Riederer, P. F. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_6 · Cited by 3
Iron Deficiency and Excess in the Brain: Implications for Cognitive Impairment and Neurodegeneration
Youdim, M. B. H., Gerlach, M., & Riederer, P. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-462-9_6 · Cited by 4
Dopamine and Neurodegeneration
Gille, G., & Riederer, P. F. (2005) · Humana Press eBooks · doi:10.1007/978-1-59259-852-6_18 · Cited by 3
Protection by Polyphenols Against Mitochondrial Damage and Cytotoxicity
Carrasco‐Pozo, C. (2013) · Polyphenols in Human Health and Disease · doi:10.1016/b978-0-12-398456-2.00057-8 · Cited by 3
Oxidative Stress with Emphasis on the Role of LAMMA in Parkinson’s Disease
Good, P. F., Perl, D. P., & Olanow, C. W. (1997) · Springer eBooks · doi:10.1007/978-1-4899-0197-2_14 · Cited by 3
Subcortical and brainstem hemiatrophy accompanied by iron deposition in a patient with hemiparkinsonism-hemiatrophy syndrome: a case report
Chung, S. J. (2021) · BMC Neurology · doi:10.1186/s12883-021-02080-4 · Cited by 2
Iron-Induced Dopaminergic Cell Death In Vivo as a Model of Parkinson’s Disease
Gerlach, M., Double, K. L., & Riederer, P. F. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_100-1 · Cited by 2
6-Hydroxydopamine (6-OHDA) rodent model of Parkinson’s disease: Investigating neural control of cardiorespiratory function
Takakura, A. C. T., Moreira, T. S., & Falquetto, B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89833-1.00046-x · Cited by 1
Neuroprotection and Neurorestoration of Nigra Striatal Dopamine Neurons by Novel Multitarget Drugs, M30
Gal-Ben-Ari, S., & Youdim, M. B. H. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_211 · Cited by 1
Neuroprotective Strategies in Parkinson’s Disease and Huntington’s Chorea
Youdim, M. B. H., Krishna, G. A., & Chiueh, C. C. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-692-8_20 · Cited by 1
Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for Neuroprotection
Grünblatt, E., Mandel, S. A., Royak, Y., & Youdim, M. B. H. (2000) · Springer eBooks · doi:10.1007/978-1-4615-1269-1_26
Autophagy: A Possible Defense Mechanism in Parkinson's Disease?
Rosa, A., Gómez‐Sánchez, R., Sanchez-, L., Pedro, J. M. B., Pizarro‐Estrella, E., Niso‐Santano, M., & José, M. V. S. (2013) · InTech eBooks · doi:10.5772/54851
Untersuchung der Plasmaoxidierbarkeit und des Antioxidantienstatus im Blutplasma von Patienten mit Morbus Parkinson: ein Beitrag zur Frage des oxidativen Streß in der Pathogenese des Morbus Parkinson
Eppendorf, U., & Greten, H. (2000)
MRI assessment of brain iron content in methamphetamine users
Berlow, Y. A. (2014) · doi:10.6083/m4028q7c
_-Synuclein and Metals
Santner, A. A., & Uversky, V. N. (2010) · CRC Press eBooks · doi:10.1201/b10278-13
The In Vitro and In Vivo Molecular Mechanisms of Neuroprotection by the Major Green Tea Polyphenol, (–)-Epigallocatechin-3-gallate, with Special Reference to Parkinson’s Disease
Mandel, S. A., Amit, T., Youdim, M. B. H., & Weinreb, O. (2005) · Oxidative stress and disease · doi:10.1201/9781420027174.ch13
Treatment with the alpha-Synuclein Oligomer Prone Mutants E35K and E57K Leads to Significant Intracellular Aggregation and Inclusion Formation
Renganathan, S. D. S., & Dushyaanthan, S. (2015) · TSpace (University of Toronto)
GDNF and Neurturin isoforms in an experimental model of Parkinson's disease
Penttinen, A. (2017) · Työväentutkimus Vuosikirja
Efeito neuroprotetor do antagonismo do receptor P2X7 no Parkinsonismo experimental induzido por 6-OHDA
do Carmo, M. R. S. (2015) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Mitochondrial Dysfunction in Aging and Neurodegeneration
Walia, V., & Garg, M. (2018) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-5282-6.ch004
What have we learnt from eDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?
oudim, M. B. H. Y. (2003)
Neuroprotection and Neurorestoration of Nigra Striatal Dopamine Neurons by Novel Multitarget Drugs, M30
Gal-Ben-Ari, S., & Youdim, M. B. H. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_211-1
Mitochondrial Dysfunction in Aging and Neurodegeneration
Walia, V., & Garg, M. (2022) · IGI Global eBooks · doi:10.4018/978-1-6684-5295-0.ch016
Iron-Induced Dopaminergic Cell Death In Vivo as a Model of Parkinson’s Disease
Gerlach, M., Double, K. L., & Riederer, P. F. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_100
Mitochondrial toxicants to model Parkinson’s disease
Currim, F., & Cannon, J. R. (2025) · Advances in neurotoxicology · doi:10.1016/bs.ant.2025.02.005
Maladie de Parkinson et DMLA : y a-t-il un lien ?
Mathis, T. (2020) · theses.fr (ABES) · doi:10.70675/fa69dd3ez4363z4b07zba8aze1d5251d827b
Levodopa increases substantia nigra iron: implications for Parkinson’s diseasePreprint
Du, G., Bransom, L., Zhou, M., Sica, C. T., Huang, X., Yang, Y., & Mailman, R. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.26.728066

Authors: Oestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., & Arendash, G. W.
Affiliations: University of Würzburg (DE)
University of South Florida (US)
Louisiana State University (US)
Corresponding author: Arendash, G.W.
ORCID: Riederer, P.
Olanow, C.W.
Arendash, G.W.
Venue: Brain Research
Publisher: Elsevier BV
Published: 1994-10
Volume: 660
Issue: 1
Pages: 8-18
ISSN: 0006-8993 (ISSN-L)
DOI: 10.1016/0006-8993(94)90833-8
OpenAlex: W2049800884
Cited by: 156
References: 47
Citations by year: 2026: 1 · 2025: 1 · 2023: 4 · 2022: 7 · 2021: 7 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 4 · 2014: 5 · 2013: 7 · 2012: 4
FWCI: 3.39
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Brain Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
Keywords: Parkinson's disease, nigrostriatal dopaminergic neurons, substantia nigra, iron accumulation, 6-hydroxydopamine lesion, neurodegeneration, reactive glial cells
MeSH terms: Amphetamine, Animals, Behavior, Animal, Corpus Striatum, Histocytochemistry, Iron, Male, Medial Forebrain Bundle, Nerve Degeneration, Neurons, Stereotyped Behavior, Substantia Nigra, Oxidopamine, Rats, Sprague-Dawley, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks